A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
High dose of Micardis®, once daily
Low dose of Micardis®, once daily
Low dose of COZAAR®, once daily
High dose of COZAAR®, once daily
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of ≥ 95 mmHg and ≤ 109 mmHg, measured by manual cuff sphygmomanometer, on the last visit (Visit 6) of the four-week placebo run-in period (baseline BP). The manual cuff value is calculated as the mean of three seated measurements taken two minutes apart, after the patient has been seated quietly for 5 minutes
- A 24-mean DBP of ≥ 85 mmHg at Visit 7 as measured by ABPM
- Age 18 years or older
- Ability to stop current antihypertensive therapy without risk to the patient (investigator's discretion)
- Ability to provide written informed consent
Exclusion Criteria:
Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who:
- are not surgically sterile; and/or
- are nursing
- are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of ≥ 3-months duration. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives
- Mean sitting SBP ≥ 180 mmHg or mean sitting DBP ≥ 110 mmHg during any visit of the placebo run-in period
Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- Serum glutamate-pyruvate-transaminase (alanine aminotransferase) or serum glutamate-oxaloacetate-transaminase (aspartate aminotransferase) greater than two times the upper limit of normal
- Serum creatinine > 2.3 mg/dL
- Clinically relevant sodium depletion, hyperkalemia, or hypokalemia
- Uncorrected volume depletion
- Primary aldosteronism
- Biliary obstructive disorders
- Known or suspected secondary hypertension
- Hereditary fructose intolerance
- Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
- Congestive heart failure (NYHA functional class congestive heart failure (CHF) class III-IV)
- Unstable angina within the past three months
- Stroke within the past six months
- Myocardial infarction or cardiac surgery within the past three months
- Percutaneous transluminal coronary angioplasty (PTCA) within the past three months
- History of angioedema
- Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
- Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
- Patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an HbA1c ≥ 10%
- Known drug or alcohol dependency within the past 6 months
- Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
- Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 ante meridien (AM)
- Patients receiving any investigational therapy within one month of signing the informed consent form
- Known hypersensitivity to any component of the formulations
- Any clinical condition which, in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Active Comparator
Active Comparator
Arm Label
Low dose of Micardis®
High dose of Micardis®
Low dose of COZAAR®
High dose of COZAAR®
Arm Description
Outcomes
Primary Outcome Measures
Change from baseline in mean diastolic blood pressure
Measured during the last 6 hours of the 24-hour dosing interval using ABPM
Secondary Outcome Measures
Change from baseline in mean systolic blood pressure
Measured during the last 6 hours of the 24-hour dosing interval using ABPM
Changes from baseline in diastolic and systolic blood pressure
Measured during other times of the 24-hour ABPM profile (e.g. 24-hour mean, morning mean, daytime mean and nighttime mean)
Changes from baseline in mean seated trough diastolic blood pressure and systolic blood pressure
Triplicate measurement in two minute intervals after 5 minutes of rest, in seated position using sphygmomanometer
Assessment of responder rates on ABPM
Assessment of responder rates on trough cuff blood pressure
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02200640
Brief Title
A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
Official Title
A Prospective, Randomized, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 & 80 mg QD) and COZAAR® (Losartan) (50 & 100 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
March 2000 (undefined)
Primary Completion Date
December 2000 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
The primary aim of the trial is to compare the influence of MICARDIS® (telmisartan 40-80 mg) and COZAAR® (losartan 50-100 mg) in lowering ambulatory diastolic blood pressure (DBP) during the last 6 hours of the 24-hour dosing interval as measured by ABPM after 8-weeks treatment. Secondary objectives include evaluations of: 1) change from baseline in mean systolic blood pressure (SBP) during the last 6 hours of the 24-hour dosing interval as measured by ABPM, 2) changes from baseline in SBP and DBP during other periods during the 24-hour ABPM profile, 3) changes from baseline in mean seated trough SBP and DBP as measured by manual cuff sphygmomanometer, and 4) responder rates based on both ABPM and trough cuff blood pressure
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
333 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low dose of Micardis®
Arm Type
Experimental
Arm Title
High dose of Micardis®
Arm Type
Experimental
Arm Title
Low dose of COZAAR®
Arm Type
Active Comparator
Arm Title
High dose of COZAAR®
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
High dose of Micardis®, once daily
Other Intervention Name(s)
Telmisartan
Intervention Type
Drug
Intervention Name(s)
Low dose of Micardis®, once daily
Other Intervention Name(s)
Telmisartan
Intervention Type
Drug
Intervention Name(s)
Low dose of COZAAR®, once daily
Other Intervention Name(s)
Losartan
Intervention Type
Drug
Intervention Name(s)
High dose of COZAAR®, once daily
Other Intervention Name(s)
Losartan
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change from baseline in mean diastolic blood pressure
Description
Measured during the last 6 hours of the 24-hour dosing interval using ABPM
Time Frame
Up to 8 weeks after start of treatment
Secondary Outcome Measure Information:
Title
Change from baseline in mean systolic blood pressure
Description
Measured during the last 6 hours of the 24-hour dosing interval using ABPM
Time Frame
Up to 8 weeks after start of treatment
Title
Changes from baseline in diastolic and systolic blood pressure
Description
Measured during other times of the 24-hour ABPM profile (e.g. 24-hour mean, morning mean, daytime mean and nighttime mean)
Time Frame
Up to 8 weeks after start of treatment
Title
Changes from baseline in mean seated trough diastolic blood pressure and systolic blood pressure
Description
Triplicate measurement in two minute intervals after 5 minutes of rest, in seated position using sphygmomanometer
Time Frame
Up to 8 weeks after start of treatment
Title
Assessment of responder rates on ABPM
Time Frame
Baseline, 8 weeks after start of treatment
Title
Assessment of responder rates on trough cuff blood pressure
Time Frame
Baseline up to 8 weeks after start of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of ≥ 95 mmHg and ≤ 109 mmHg, measured by manual cuff sphygmomanometer, on the last visit (Visit 6) of the four-week placebo run-in period (baseline BP). The manual cuff value is calculated as the mean of three seated measurements taken two minutes apart, after the patient has been seated quietly for 5 minutes
A 24-mean DBP of ≥ 85 mmHg at Visit 7 as measured by ABPM
Age 18 years or older
Ability to stop current antihypertensive therapy without risk to the patient (investigator's discretion)
Ability to provide written informed consent
Exclusion Criteria:
Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who:
are not surgically sterile; and/or
are nursing
are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of ≥ 3-months duration. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives
Mean sitting SBP ≥ 180 mmHg or mean sitting DBP ≥ 110 mmHg during any visit of the placebo run-in period
Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
Serum glutamate-pyruvate-transaminase (alanine aminotransferase) or serum glutamate-oxaloacetate-transaminase (aspartate aminotransferase) greater than two times the upper limit of normal
Serum creatinine > 2.3 mg/dL
Clinically relevant sodium depletion, hyperkalemia, or hypokalemia
Uncorrected volume depletion
Primary aldosteronism
Biliary obstructive disorders
Known or suspected secondary hypertension
Hereditary fructose intolerance
Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
Congestive heart failure (NYHA functional class congestive heart failure (CHF) class III-IV)
Unstable angina within the past three months
Stroke within the past six months
Myocardial infarction or cardiac surgery within the past three months
Percutaneous transluminal coronary angioplasty (PTCA) within the past three months
History of angioedema
Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
Patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an HbA1c ≥ 10%
Known drug or alcohol dependency within the past 6 months
Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 ante meridien (AM)
Patients receiving any investigational therapy within one month of signing the informed consent form
Known hypersensitivity to any component of the formulations
Any clinical condition which, in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com
Description
Related Info
Learn more about this trial
A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
We'll reach out to this number within 24 hrs